ArticleAmerican journal of translational research2015
MicroRNA-495 suppresses human renal cell carcinoma malignancy by targeting SATB1.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 28 citations in OpenAlex.
- MicroRNA-495: a therapeutic and diagnostic tumor marker.Journal of molecular histology · 2023Review
- MicroRNA-100 Enhances Autophagy and Suppresses Migration and Invasion of Renal Cell Carcinoma Cells via Disruption of NOX4-Dependent mTOR Pathway.Clinical and translational science · 2022Article
- DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers.BMC cancer · 2021Article
- MiR-495 regulates macrophage M1/M2 polarization and insulin resistance in high-fat diet-fed mice via targeting FTO.Pflugers Archiv : European journal of physiology · 2019Article
- miR-7-5p inhibits cell migration and invasion in glioblastoma through targeting SATB1.Oncology letters · 2019Article
- Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.Cancer gene therapy · 2018Article
- Circulating microRNA signature of steroid-induced osteonecrosis of the femoral head.Cell proliferation · 2018Article
- MicroRNA-495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin-like growth factor receptor-1.Experimental and therapeutic medicine · 2018Article
- MicroRNA-138 suppresses cell proliferation and invasion of renal cell carcinoma by directly targeting SOX9.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deregulated expression of miRNAs is related to progression and initiation of human cancers. Although miR-495 has identified in various tumors, its expression and function in renal cell carcinoma (RCC) is still unknown. In this study, we found that the expression of miR-495 was downregulated in RCC cell lines and tissues. Ectopic expression of miR-495 induced G0/G1 phase arrest and suppressed cell proliferation and migration in RCC cell lines. We further validated SATB1 was a direct target of miR-495 in RCC. In addition, re-expression of SATB1 reversed the miR-495-induced inhibition of cell proliferation and migration. These data suggest that miR-495 functions as a tumor suppressor and may be a promising therapeutic target in RCC in the future.
Indexed as
Identifiers
26692942PMC4656775W2224281762What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.